StockNews.com Begins Analyst Coverage on Cellectis SA with a Hold Rating

Financial analysis platform StockNews.com has recently initiated their coverage on Cellectis SA CLLS, a Paris-based clinical-stage biotechnology company specializing in the development of gene-edited T cells for immuno-oncology applications. In an analytical report released on Monday, the firm assigned a ‘hold’ rating to the company’s stock, indicating a neutral stance on the investment prospect of the biotech entity.

Analyst Ratings and Market Sentiment

The coverage by StockNews.com complements a range of assessments already conducted by various research entities. Notably, Oppenheimer has reiterated an 'outperform' rating suggesting confidence in the stock's potential with an $11.00 target price. Additionally, JMP Securities has maintained a 'market outperform' label coupled with a $6.00 target price on the shares of Cellectis. Overall, the consensus rating for CLLS, pulling together all analyst opinions, aligns with a 'Moderate Buy' recommendation with an average target price of approximately $9.75, per data curated by MarketBeat.

Cellectis’ Financial Health and Stock Performance

The company stock for Cellectis opened at a price of $2.51 this past Monday. Investors are keeping an eye on the Cellectis’ financial metrics such as its 50-day and 200-day moving average price, sitting at $1.67 and $1.87 respectively. The biotech firm currently holds a market capitalization near $139.52 million, with a trailing price-to-earnings ratio at -1.50 and showcasing a beta of 2.23. The company’s balance sheet indicates a debt-to-equity ratio of 0.57, a quick ratio of 2.69, and a current ratio of 2.20.

Institutional Investors’ Engagement

In a demonstration of the investment community’s engagement with Cellectis, a variety of hedge funds have recently adjusted their stakes in the company. Two Sigma Investments LP, Virtu Financial LLC, and Balyasny Asset Management LLC are among those that have initiated positions in CLLS. In contrast, entities like Envestnet Asset Management Inc. ENV, a firm offering wealth management software and services, increased their holdings in Cellectis by 19.2% in the first quarter. According to the last quarterly reports, approximately 25.20% of Cellectis shares are held by institutional investors and hedge funds.

About Cellectis SA

CLLS represents Cellectis SA and its pioneering work in the field of cancer treatment. The biotech company’s flagship product candidates include UCART19, designed to treat acute lymphoblastic leukemia, and ALLO-501/ALLO-501A for relapsed or refractory non-Hodgkin lymphoma, as well as ALLO-715 targeting multiple myeloma. These innovative solutions are predicated on the utility of chimeric antigen receptors in T cells, engineered to target cancer cells specifically, offering a promising avenue in the fight against malignancies.

StockNews, Analysis, Cellectis